CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
99.20
0.1%
Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.90
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022102 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022102%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000121 %
Charges from full value of position ($-0.02)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000121%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Biomerieux SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 99.1
Open* 98
1-Year Change* 3.1%
Day's Range* 97.2 - 99.6
52 wk Range 84.54-101.80
Average Volume (10 days) 70.20K
Average Volume (3 months) 1.64M
Market Cap 11.85B
P/E Ratio 30.75
Shares Outstanding 118.12M
Revenue 3.70B
EPS 3.26
Dividend (Yield %) 0.84915
Beta -0.01
Next Earnings Date Mar 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 99.20 1.80 1.85% 97.40 99.65 96.95
Apr 18, 2024 99.10 -0.70 -0.70% 99.80 100.30 98.20
Apr 17, 2024 100.70 3.60 3.71% 97.10 102.20 96.80
Apr 16, 2024 101.80 -0.30 -0.29% 102.10 103.10 100.80
Apr 15, 2024 105.30 1.00 0.96% 104.30 105.70 103.30
Apr 12, 2024 104.90 -0.20 -0.19% 105.10 107.00 104.20
Apr 11, 2024 104.30 0.70 0.68% 103.60 105.70 103.30
Apr 10, 2024 103.40 -3.90 -3.63% 107.30 108.50 103.00
Apr 9, 2024 106.20 6.00 5.99% 100.20 106.20 99.20
Apr 8, 2024 97.30 2.60 2.75% 94.70 97.35 94.65
Apr 5, 2024 94.85 0.55 0.58% 94.30 95.95 93.90
Apr 4, 2024 97.05 -1.40 -1.42% 98.45 99.00 96.00
Apr 3, 2024 99.00 -2.70 -2.65% 101.70 102.00 98.95
Apr 2, 2024 101.90 0.10 0.10% 101.80 103.50 100.30
Mar 28, 2024 101.95 2.00 2.00% 99.95 102.80 99.80
Mar 27, 2024 100.75 0.25 0.25% 100.50 101.05 99.60
Mar 26, 2024 100.60 0.80 0.80% 99.80 100.85 99.50
Mar 25, 2024 100.45 0.85 0.85% 99.60 101.00 99.00
Mar 22, 2024 99.60 0.20 0.20% 99.40 99.65 98.20
Mar 21, 2024 100.15 0.60 0.60% 99.55 100.75 99.20

Biomerieux Events

Time (UTC) Country Event
Thursday, May 23, 2024

Time (UTC)

07:00

Country

FR

Event

Biomerieux SA Annual Shareholders Meeting
Biomerieux SA Annual Shareholders Meeting

Forecast

-

Previous

-

Time (UTC)

07:00

Country

FR

Event

Biomerieux SA Extraordinary Shareholders Meeting
Biomerieux SA Extraordinary Shareholders Meeting

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

12:00

Country

FR

Event

Biomerieux SA
Biomerieux SA

Forecast

-

Previous

-
Monday, June 10, 2024

Time (UTC)

12:00

Country

FR

Event

Biomerieux SA
Biomerieux SA

Forecast

-

Previous

-
Wednesday, September 4, 2024

Time (UTC)

10:59

Country

FR

Event

Half Year 2024 Biomerieux SA Earnings Call
Half Year 2024 Biomerieux SA Earnings Call

Forecast

-

Previous

-

Time (UTC)

10:59

Country

FR

Event

Half Year 2024 Biomerieux SA Earnings Release
Half Year 2024 Biomerieux SA Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Revenue 3589.1 3376.2 3118.2 2674.8 2421.3
Cost of Revenue, Total 1580.4 1375.4 1364.5 1208.2 1119
Gross Profit 2008.7 2000.8 1753.7 1466.6 1302.3
Total Operating Expense 3001.9 2591.3 2566 2304.1 2075.2
Selling/General/Admin. Expenses, Total 954.7 815.6 789.3 749.8 643.1
Research & Development 446.6 385.8 398.8 374.3 326.9
Depreciation / Amortization 76.6 59.7 17.5 17.9 17.5
Unusual Expense (Income) -0.6 0.6
Other Operating Expenses, Total -56.4 -44.6 -4.7 -46.1 -31.3
Operating Income 587.2 784.9 552.2 370.7 346.1
Interest Income (Expense), Net Non-Operating -4.3 -11.7 -29.1 -23.8 -26.7
Other, Net -2.3 1.3 1.2 0.7 -1.9
Net Income Before Taxes 580.6 774.5 524.3 347.6 317.5
Net Income After Taxes 440.5 598.9 402.8 269.8 252.4
Minority Interest 11.8 2.9 1.7 3.1 1.1
Equity In Affiliates 0 -0.7 -0.2 0 0.2
Net Income Before Extra. Items 452.3 601.1 404.3 272.9 253.7
Net Income 452.3 601.1 404.3 272.9 253.7
Total Adjustments to Net Income 0.1 0 0.1 -0.1 2.8
Income Available to Common Excl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Income Available to Common Incl. Extra. Items 452.4 601.1 404.4 272.8 256.5
Diluted Net Income 452.4 601.1 404.4 272.8 256.5
Diluted Weighted Average Shares 118.441 118.893 118.592 118.609 118.203
Diluted EPS Excluding Extraordinary Items 3.81964 5.05579 3.41 2.3 2.17
Dividends per Share - Common Stock Primary Issue 0.85 0.85 0.62 0.19 0.35
Diluted Normalized EPS 3.81964 5.05189 3.41389 2.3 2.17
Dilution Adjustment 0
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 1770.1 1931.1 1658 1802 1574.2
Revenue 1770.1 1931.1 1658 1802 1574.2
Cost of Revenue, Total 770.9 860.4 720 721.6 659.2
Gross Profit 999.2 1070.7 938 1080.4 915
Total Operating Expense 1562.3 1641 1360.9 1383.5 1208.4
Selling/General/Admin. Expenses, Total 502.1 514.4 440.3 436.9 379.6
Research & Development 226.5 239.3 207.3 204.8 181.5
Depreciation / Amortization 83.6 51.7 24.9 44.6 8.3
Other Operating Expenses, Total -20.8 -24.8 -31.6 -24.4 -20.2
Operating Income 207.8 290.1 297.1 418.5 365.8
Interest Income (Expense), Net Non-Operating 0.9 2.8 -7.1 -4.7 -7
Other, Net -0.4 -3.8 1.5 1.3 0.6
Net Income Before Taxes 208.3 289.1 291.5 415.1 359.4
Net Income After Taxes 138.7 214.2 226.3 322 276.9
Minority Interest 22.9 10 1.8 1.8 1.1
Equity In Affiliates 0 0 0 0.2 -0.9
Net Income Before Extra. Items 161.6 224.2 228.1 324 277.1
Net Income 161.6 224.2 228.1 324 277.1
Income Available to Common Excl. Extra. Items 161.6 224.4 228 324 277.1
Income Available to Common Incl. Extra. Items 161.6 224.4 228 324 277.1
Diluted Net Income 161.6 224.4 228 324 277.1
Diluted Weighted Average Shares 118.613 118.533 118.349 119.1 118.927
Diluted EPS Excluding Extraordinary Items 1.36241 1.89315 1.92651 2.7204 2.33
Dividends per Share - Common Stock Primary Issue 0 0.85 0 0.85 0
Diluted Normalized EPS 1.36241 1.89315 1.92651 2.7204 2.33
Total Adjustments to Net Income 0.2 -0.1 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2216.7 2184.6 1661.6 1438.5 1314.4
Cash and Short Term Investments 552.6 803.5 389.2 275 288.3
Cash 401.7 547.1 313.5 241 239.9
Cash & Equivalents 150.9 256.4 75.7 34 48.4
Total Receivables, Net 926.9 761 730.4 668.8 607.3
Accounts Receivable - Trade, Net 740.1 590.6 597.9 552.1 491.8
Total Inventory 737.2 620 541.9 494.7 418.8
Other Current Assets, Total 0.1 0.1
Total Assets 5186.6 4605 3927.8 3781.9 3501.6
Property/Plant/Equipment, Total - Net 1369.9 1224.8 1068.6 1025.2 899.1
Property/Plant/Equipment, Total - Gross 2703.9 2447.7 2173.3 2100.9 1899.4
Accumulated Depreciation, Total -1334.1 -1222.7 -1104.7 -1075.7 -1000.5
Goodwill, Net 812.5 669.5 629.4 652.5 619
Intangibles, Net 625 411.5 430.7 508.4 507.2
Long Term Investments 71.2 62 39.9 31.7 59.2
Note Receivable - Long Term 19.8 10.7 10.4 8
Other Long Term Assets, Total 71.5 52.6 86.9 115.2 94.7
Total Current Liabilities 1131.1 955.7 923.8 1170.1 796.3
Accounts Payable 269.4 239.5 207.1 211.9 179.7
Accrued Expenses 372.6 327.4 283.3 262.4
Notes Payable/Short Term Debt 23.9 0 0 0 0
Current Port. of LT Debt/Capital Leases 163.1 99.7 128.9 438.6 129.1
Other Current Liabilities, Total 302.1 616.5 260.4 236.3 225.1
Total Liabilities 1582.4 1492.8 1496.7 1578 1572.8
Total Long Term Debt 318.4 362.8 352.4 153.7 524.9
Long Term Debt 224.7 362.8 352.4 153.7 524.9
Deferred Income Tax 53 60.3 105.8 141.2 130.5
Minority Interest 38.7 51.4 50.2 50.7 74.1
Other Liabilities, Total 41.2 62.6 64.5 62.3 47
Total Equity 3604.2 3112.2 2431.1 2203.9 1928.8
Common Stock 12 12 12 12 12
Additional Paid-In Capital 3062.2 2532.1 2204.7 1933.4 1712.2
Retained Earnings (Accumulated Deficit) 410.4 542.5 344.7 207.9 210.1
Treasury Stock - Common -36 -10.3 -23 -3.9 -32.8
Other Equity, Total 155.6 35.9 -107.3 54.5 27.3
Total Liabilities & Shareholders’ Equity 5186.6 4605 3927.8 3781.9 3501.6
Total Common Shares Outstanding 118 118.282 118.16 118.324 117.819
Capital Lease Obligations 93.7
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 2152.7 2216.7 2058.4 2184.6 1798.7
Cash and Short Term Investments 423 552.6 524.2 803.5 493.2
Cash 320.2 401.7 365.6 803.5 363.3
Cash & Equivalents 102.8 150.9 158.6 129.9
Total Receivables, Net 888.9 926.9 825.7 761 694.5
Accounts Receivable - Trade, Net 657.7 740.1 624.2 590.6 542.4
Total Inventory 840.9 737.2 708.5 620 611
Total Assets 5030.9 5186.6 5041.2 4605 4157.2
Property/Plant/Equipment, Total - Net 1392 1369.9 1314.4 1224.8 1135.2
Property/Plant/Equipment, Total - Gross 2782.4 2703.9 2620.7 2447.7 2306.1
Accumulated Depreciation, Total -1390.4 -1334 -1306.2 -1222.7 -1170.8
Goodwill, Net 734.4 812.5 877.5 669.5 642.4
Intangibles, Net 592.5 625 667.5 411.5 426.8
Long Term Investments 89.2 91 48 62 56.6
Other Long Term Assets, Total 70.1 71.5 75.4 52.6 97.5
Total Current Liabilities 980.7 1131.1 1020.7 955.7 857.9
Accounts Payable 243.5 269.4 243.4 239.5 199.1
Notes Payable/Short Term Debt 22.4 23.9 11 0 0
Current Port. of LT Debt/Capital Leases 138.2 163.1 215 99.7 163.2
Other Current Liabilities, Total 576.6 674.7 551.3 616.5 495.6
Total Liabilities 1403.6 1582.4 1572.2 1492.8 1459
Total Long Term Debt 330.1 318.4 365.7 362.8 361.5
Long Term Debt 231.7 224.7 272 362.8 361.5
Deferred Income Tax 33.9 53 97.2 60.3 124.7
Minority Interest 14.2 38.7 44.9 51.4 50.8
Other Liabilities, Total 44.7 41.2 43.7 62.6 64.1
Total Equity 3627.3 3604.2 3469 3112.2 2698.2
Common Stock 12 12 12.2 12 12
Additional Paid-In Capital 3416.3 3062.2 3174.3 2532.1 2528.8
Retained Earnings (Accumulated Deficit) 120.2 410.4 183.5 542.5 219.5
Treasury Stock - Common -20.9 -36 -152.3 -10.3 -16.6
Other Equity, Total 99.7 155.6 251.3 35.9 -45.5
Total Liabilities & Shareholders’ Equity 5030.9 5186.6 5041.2 4605 4157.2
Total Common Shares Outstanding 118.124 118 119.507 118.282 118.095
Other Current Assets, Total -0.1 0.1
Capital Lease Obligations 98.4 93.7 93.7
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 440.5 598.2 402.7 269.7 255.6
Cash From Operating Activities 475.1 824.7 582.8 407.9 399.7
Cash From Operating Activities 67 58.8 210.8 189.5 177
Non-Cash Items 264.8 176.7 159 45.5 12.3
Cash Taxes Paid 223.5 185.4 115.9 81.6 66.5
Cash Interest Paid
Changes in Working Capital -297.2 -9 -189.7 -96.8 -45.2
Cash From Investing Activities -528.1 -307.3 -265.2 -282.2 -413.1
Capital Expenditures -286.7 -290.1 -277.5 -272.5 -226.4
Other Investing Cash Flow Items, Total -241.4 -17.2 12.3 -9.7 -186.7
Cash From Financing Activities -244.2 -140.6 -176.2 -133.9 43
Financing Cash Flow Items -0.1 -2.4 -23.4 0
Total Cash Dividends Paid -101.2 -73.1 -22.5 -41.3 -40.2
Issuance (Retirement) of Stock, Net -157.2 -17.4 -16.8 0 -22.3
Issuance (Retirement) of Debt, Net 14.3 -50.1 -134.5 -69.2 105.5
Foreign Exchange Effects 38.7 39.2 -34.1 -6.1 -11.8
Net Change in Cash -258.5 416 107.3 -14.3 17.8
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Net income/Starting Line 440.5 226.2 598.2 276
Cash From Operating Activities 475.1 150.9 824.7 285.8
Cash From Operating Activities 67 100.4 58.8 97.2
Non-Cash Items 264.8 -27.4 176.7 -66.4
Cash Taxes Paid 223.5 145.4 185.4 98.1
Changes in Working Capital -297.2 -148.3 -9 -21
Cash From Investing Activities -528.1 -352.3 -307.3 -143.4
Capital Expenditures -286.7 -152.8 -290.1 -143.5
Other Investing Cash Flow Items, Total -241.4 -199.5 -17.2 0.1
Cash From Financing Activities -244.2 -127.8 -140.6 -73.8
Total Cash Dividends Paid -101.2 -101.2 -73.1 -73.1
Issuance (Retirement) of Stock, Net -157.2 -111.3 -17.4 -2.5
Issuance (Retirement) of Debt, Net 14.3 84.8 -50.1 1.8
Foreign Exchange Effects 38.7 55.2 39.2 12.8
Net Change in Cash -258.5 -274 416 81.4
Financing Cash Flow Items -0.1 -0.1

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biomerieux Company profile

About BioMerieux SA

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.

Equity composition

9/2017, 3-for-1 stock split (Factor: 3).

Industry: Laboratory Diagnostic & Testing Substances

376, chemin de l'Orme
CRAPONNE
AUVERGNE-RHONE-ALPES 69280
FR

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,182.37 Price
+0.970% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.54 Price
+0.600% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading